PubMed · 14899364
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
W BLECHSCHMIDT. 1951-10-27. [Hemangioma therapy].. https://pubmed.ncbi.nlm.nih.gov/14899364/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Kasabach-Merritt Syndrome (KMS) originally referred to a hemangioma associated with life-threatening thrombocytopenia and a consumption coagulopathy. Treatment includes surgery, steroids, and alpha interferon. However response may be unsatisfactory and mortality rates of 10-37% have been reported. We report a case of a 4-month-old male whose disease had not responded to steroids and alpha interferon. He required ventilation, and his condition was deteriorating. It was thought that he would probably die of his condition. He was treated with 9 Gy in three fractions weekly of radiotherapy (RT). Clinical response was good and he is well and free from progression 4 years and 7 months after RT. A review of the literature on the role of RT in the management of hemangiomas is presented.
Infantile haemangiomas are the commonest tumours occurring in infants, but regress spontaneously without causing major problems in the great majority of cases. However, in some infants they can cause life-threatening complications. Fortunately, if the decision to treat is made promptly, and the most appropriate form of treatment selected, these complications can usually be prevented.
Explore the source record for details and available documents.